Current role of ceftobiprole in the treatment of hospital-acquired and community-acquired pneumonia: expert opinion based on literature and real-life experiences
Open Access
- 5 February 2025
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 23 (2-4) , 217-225
Abstract
Community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) are major global health challenges, with high morbidity and mortality rates. The increasing prevalence of multidrug-resistant (MDR) bacteria may diminish the effectiveness of standard empirical antibiotics, highlighting the need for broader-spectrum agents that target also MDR organisms. This review summarizes findings from a PubMed search on the use of ceftobiprole in CAP and HAP. It highlights key features of ceftobiprole, including its mechanism of action and broad spectrum of activity against multiple MDR pathogens. Clinical data from randomized controlled trials and real-world studies underscore its non-inferiority to standard treatments, with favorable safety profile and high clinical cure rates even in challenging cases. Ceftobiprole represents a valid option for the patients with CAP and HAP. Its main advantages include its broad spectrum of activity, making it a valuable therapeutic choice for treating polymicrobial infections, and its favorable safety profile, which makes it a good candidate in elderly patients with multiple comorbidities and polypharmacy. Caution is advised in patients at high risk of ESBL-producing organisms or MDR Pseudomonas aeruginosa infections, where combination therapy is recommended. Moreover, therapeutic drug monitoring is recommended to improve outcomes, particularly in complex clinical conditions.Keywords
Funding Information
- Advanz Pharma
This publication has 64 references indexed in Scilit:
- Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020Diagnostic Microbiology and Infectious Disease, 2022
- Bloodstream infections in patients with rectal colonization by Klebsiella pneumoniae producing different type of carbapenemases: a prospective, cohort study (CHIMERA study)Clinical Microbiology and Infection, 2022
- Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016–2017)Diagnostic Microbiology and Infectious Disease, 2019
- Burden of Pneumonia-Associated HospitalizationsChest, 2018
- Predictors of mortality in nursing-home residents with pneumonia: a multicentre studyClinical Microbiology and Infection, 2018
- Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient PopulationsClinical Pharmacokinetics, 2016
- Ceftobiprole Medocaril: A Review of Its Use in Patients with Hospital- or Community-Acquired PneumoniaDrugs, 2014
- Performance of PSI, CURB-65, and SCAP scores in predicting the outcome of patients with community-acquired and healthcare-associated pneumoniaInternal and Emergency Medicine, 2011
- Pharmacokinetic and pharmacodynamic profile of ceftobiproleDiagnostic Microbiology and Infectious Disease, 2008
- Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolatesDiagnostic Microbiology and Infectious Disease, 2004